BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioDelivery Sciences International (BDSI) Announces Proposed Licensing Agreement With Sigma-Tau S.p.A.


10/19/2005 5:11:27 PM

BioDelivery Sciences International (Nasdaq:BDSI) announced today it has come to an oral understanding to license to Sigma-Tau S.p.A., the right to utilize BioDelivery's proprietary formulation and delivery technology in connection with different compounds, with particular focus in the area of oncology. Under the terms of the proposed licensing agreement, which is subject to further negotiation and execution, Sigma-Tau would pay to BDSI an initial $250,000 up-front payment, upon the signing of this letter of intent and an additional $750,000 to be paid upon the accomplishment of certain milestones leading to the filing of the first IND of a compound formulated with BioDelivery's formulation and drug delivery technology. It is anticipated that should a final definitive license agreement be executed by the parties, that BioDelivery would receive additional milestone payments throughout the clinical development of each proposed product, as well as royalties on net sales.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES